Clinical Trial Update: A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity [Phase 1]

View source ↗

Summary

This Phase 1 trial investigates the effects of daily 50 mg semaglutide on food intake and gastric emptying in adults with obesity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• semaglutide (semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Obesity | Phase 1 | Status: COMPLETED